Coverage
Filings
Orion has secured an exclusive license for an experimental cancer antibody from Abzena, the latest in a series of deals to strengthen its oncology pipeline following a recent clinical trial failure.
Finnish drugmaker Orion Corp. said Tuesday its experimental insomnia drug failed a mid-stage clinical trial, days after investment giant BlackRock Inc. cut its stake in the company.
Orion and its partner Bayer have secured European Union approval for an expanded use of their blockbuster prostate cancer drug, Nubeqa, the latest in a series of regulatory wins for the treatment.
Orion Corp. reported a 59% surge in second-quarter operating profit, driven by strong sales and royalty income from its blockbuster prostate cancer drug, Nubeqa.
Finnish drugmaker Orion on Wednesday raised its full-year 2025 forecast, citing stronger-than-expected product sales and royalty income.
A European Medicines Agency panel recommended expanding the use of a prostate cancer drug from Orion and its partner Bayer, moving the blockbuster treatment a step closer to a third approval in the region.
| 27 Jan 2017 |
| Publishing of Orion Corporation's Financial Statement Release for 2016 on 8 February 2017 | 25 Jan 2017 |
| Recommendation by the Nomination Committee concerning Board of Directors to be elected by the 2017 AGM of Orion Corporation | 24 Jan 2017 |
| 87,000 Orion Corporation A shares converted into B shares | 22 Dec 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 15 Dec 2016 |
| 100,000 Orion Corporation A shares converted into B shares | 18 Nov 2016 |